The state has enjoyed success funding and building life sciences companies, and the new Indiana Biosciences Research Institute should give it a further boost, according to panelists Friday at IBJ's Life Sciences Power Breakfast.
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
Anthem turned out unheard of gains in 2014, the first year of Obamacare’s new health insurance overhaul, as Anthem’s customers numbers held steady but their spending with hospitals and doctors plummeted.
State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer's drug.
The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.
The plan by the Medicare program to require hospitals in Indianapolis and 74 other cities to accept one payment for joint replacement surgeries is a huge step in fixing the crazy prices and spending growth in health care.
With Anthem and IU Health so hot to trot their anti-smoking bona fides, it’s surprising their responses to The New York Times' stories about the U.S. Chamber of Commerce blocking anti-smoking policies overseas have been so tepid.
The money, known as reinsurance payments, helped MDwise, Anthem, Humana, Assurant and the Physicians Health Plan of Northern Indiana keep a lid on their losses even as lots of new patients with expensive or untreated medical conditions migrated into the private insurance market.